| Revenue Growth | Total revenue $150.7M, up 1%; spatial consumables up 16%; instruments down 43%. |
|---|---|
| Mgmt Confidence | High confidence in ATERA demand; production capacity is the primary bottleneck. |
| Demand Visibility | Strong ATERA orders; demand not a bottleneck; 100+ Catalyst service customers. |
| Order Book | Backlog numbers not shared; management cited 'lots and lots of orders'. |
| Margin Trends | Q3 gross margin 75%; Q4 expected step-down to low-to-mid 60s. |
| Op. Leverage | Operating expenses decreased to $129M from $132.5M year-over-year. |
| Pricing Power | Flex Apex has lower per-reaction pricing, creating top-line pressure. |
| Vol vs Price | Single-cell growth driven by double-digit reaction volumes; price stabilization noted. |
| Segment Growth | Spatial consumables outperforming; Chromium instrument revenue declined 23%. |
| New Clients | Top 20 biopharma companies purchased ATERA; Fred Hutch clinical collaboration announced. |
| Capex & Debt | Ended quarter with $576M cash; no new debt or M&A mentioned. |
| Regulatory | Standing up internal CLIA lab for 2027 launch; litigation expenses higher. |
| Commentary | Biology entering AI era; ATERA provides critical data for training models. |
| New Launches | ATERA commercial shipments started; Centira cloud analysis platform and Flex Apex CRISPR. |
Growth
Revenue $150.7M (up 1%); spatial consumables grew 16%; single-cell consumables grew 1%.
Outlook
Raised FY2026 revenue guidance to $625M-$635M; shipping 50 ATERA units by year-end.
Risks
Management avoided specific backlog numbers; gross margins expected to drop to low-to-mid 60s in Q4.
The company's earnings call, NASDAQ: TXG, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
10x Genomics, Inc.: key numbers
- Share price
- $54.99Close, Nov 16
- Sector
- Industrial Applications and Services
- Industry
- Laboratory Analytical InstrumentsSIC 3826
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from 10x Genomics, Inc.
All →10x Genomics CEO Serge Saxonov Sells $1.95M of Stock
Serge Saxonov, CEO, sold 31,000 shares of 10x Genomics, Inc. at $62.90 a share, worth $1.95M in total on Nov 10, 2026. Shares held after the trade: 1,019,249 (-3.0%).
- Value
- $1.95M
- Shares
- 31,000
- Price
- $62.90
- Role
- CEO
- Holding change
- -3.0%
- Trade date
- Nov 10, 2026
10x Genomics Q3 2026 Results: Net Loss of $19.4M, Loss Narrows
10x Genomics, Inc. reported its third quarter 2026 results, highlighting continued revenue growth driven by its spatial biology and single-cell analysis platforms. The company maintained its full-year revenue guidance while noting improvements in gross margins due to manufacturing efficiencies.
- Key figure
- Net loss $19.4M
10x Genomics Financial Results
10x Genomics reported Q3 2026 revenue of $150.7 million, a 1% increase year-over-year, and narrowed its net loss to $19.4 million. The company began commercial shipments of its Atera platform and raised its full-year 2026 revenue guidance to a range of $625 million to $635 million.
- Term
- Q3 2026
“The biggest highlight of the quarter was the start of commercial shipments of Atera. Enthusiasm for the platform has continued to build, and we are incredibly excited to be putting instruments in customers’ hands. We were also encouraged with the results across our broader business, driven by continued strength in consumables.”
Serge Saxonov, Co-founder and CEO of 10x Genomics
“As biology is entering a new era of AI and data maximalism, 10x is positioned incredibly well to benefit and to be the key enabler of progress going forward.”
Serge Saxonov, Co-founder and CEO of 10x Genomics
10x Genomics Executive Compensation
10x Genomics appointed Ansuman Satpathy and Joseph Gilliam to its Board of Directors as Class III directors. Both will receive compensation under the company's Non-Employee Director Compensation Policy, including an annual cash retainer of $60,000 and a one-time restricted stock unit grant valued at $400,000.